{"id":5822,"date":"2024-10-10T06:39:10","date_gmt":"2024-10-10T11:39:10","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5822"},"modified":"2025-06-27T08:35:21","modified_gmt":"2025-06-27T13:35:21","slug":"nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u85acMCO-010\u306eBLA\u7533\u8acb\u8a08\u753b\u3092\u767a\u8868"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<header class=\"container release-header\">\n<div class=\"custom-container\">\n<div class=\"row\">\n<div class=\"col-sm-12 col-xs-12\"><i style=\"color: #323334; font-size: revert; font-weight: 600; letter-spacing: -0.4095px;\">\u751f\u7523\u7684\u306aFDA\u4f1a\u8b70<\/i><i style=\"color: #323334; font-size: revert; font-weight: 600; letter-spacing: -0.4095px;\">\u00a02025\u5e74\u7b2c1\u56db\u534a\u671f\u306bMCO-010\u306eBLA\u7533\u8acb\u3078\u306e\u9053\u3092\u958b\u304f<\/i><\/div>\n<\/div>\n<\/div>\n<\/header>\n<\/div>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">\u30c0\u30e9\u30b9<\/span><\/span>, \u30c6\u30ad\u30b5\u30b9\u5dde \u2014 <span class=\"legendSpanClass\"><span class=\"xn-chron\">2024\u5e7410\u670810\u65e5<\/span><\/span>\u00a0 \u2014 <a href=\"https:\/\/nanostherapeutics.com\/ja\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>\u7db2\u819c\u5909\u6027\u75be\u60a3\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u3092\u958b\u767a\u3057\u3066\u3044\u308b\u5f8c\u671f\u81e8\u5e8a\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308bNanoscope\u306f\u672c\u65e5\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066MCO-010\u3092\u8a55\u4fa1\u3059\u308b\u81e8\u5e8a\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u95a2\u3059\u308b\u751f\u7523\u7684\u306aFDA\u4f1a\u8b70\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u4f1a\u8b70\u3067\u63d0\u4f9b\u3055\u308c\u305f\u898f\u5236\u5f53\u5c40\u304b\u3089\u306e\u30d5\u30a3\u30fc\u30c9\u30d0\u30c3\u30af\u306b\u57fa\u3065\u304d\u3001Nanoscope\u306f2025\u5e74\u7b2c1\u56db\u534a\u671f\u306b\u751f\u7269\u88fd\u5264\u30e9\u30a4\u30bb\u30f3\u30b9\u7533\u8acb\uff08BLA\uff09\u306e\u63d0\u51fa\u3092\u958b\u59cb\u3059\u308b\u4e88\u5b9a\u3067\u3059\u3002<\/p>\n<p>\u4eca\u56de\u306e\u4f1a\u5408\u306b\u95a2\u9023\u3057\u3066\u3001FDA\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306b\u3088\u308b\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u306e\u6cbb\u7642\u85ac\u3067\u3042\u308bMCO-010\u306e\u751f\u7269\u88fd\u5264\u627f\u8a8d\u7533\u8acb\uff08BLA\uff09\u3092\u5186\u6ed1\u306b\u9032\u3081\u308b\u305f\u3081\u306eNanoscope\u793e\u306e\u63d0\u6848\u3057\u305f\u6b21\u306e\u30b9\u30c6\u30c3\u30d7\u3092\u627f\u8a8d\u3057\u305f\u3002Nanoscope\u793e\u306f\u3001\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u306b\u57fa\u3065\u304d\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u3088\u308b\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u306e\u6cbb\u7642\u85ac\u3067\u3042\u308bMCO-010\u306eBLA\u3092\u6bb5\u968e\u7684\u306b\u63d0\u51fa\u3059\u308b\u8a08\u753b\u306e\u6982\u8981\u3092\u8aac\u660e\u3057\u305f\u3002.<\/p>\n<p>RP \u3068\u8a3a\u65ad\u3055\u308c\u305f\u4eba\u306f\u3001\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u306b\u9665\u308b\u3053\u3068\u304c\u591a\u304f\u3001\u6700\u7d42\u7684\u306b\u306f\u5931\u660e\u306b\u81f3\u308a\u307e\u3059\u3002\u73fe\u5728\u306e\u6cbb\u7642\u30d1\u30e9\u30c0\u30a4\u30e0\u306f\u8996\u529b\u30ea\u30cf\u30d3\u30ea\u30c6\u30fc\u30b7\u30e7\u30f3\u306b\u91cd\u70b9\u3092\u7f6e\u3044\u3066\u3044\u307e\u3059\u304c\u3001\u60a3\u8005\u306f\u751f\u6daf\u306b\u308f\u305f\u3063\u3066\u9032\u884c\u6027\u306e\u8996\u529b\u969c\u5bb3\u306b\u8010\u3048\u306a\u3051\u308c\u3070\u306a\u3089\u305a\u3001\u751f\u6d3b\u306e\u8cea\u306b\u5287\u7684\u306a\u5f71\u97ff\u3092\u53ca\u307c\u3057\u307e\u3059\u3002<\/p>\n<p>\u201c\u300c\u6570\u5e74\u306b\u308f\u305f\u308b\u30d9\u30fc\u30b9\u30e9\u30a4\u30f3\u8996\u529b\u306e\u7dad\u6301\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306e\u4e88\u60f3\u3055\u308c\u308b\u81ea\u7136\u7d4c\u904e\u304b\u3089\u9038\u8131\u3059\u308b\u91cd\u8981\u306a\u6cbb\u7642\u52b9\u679c\u3092\u793a\u3059\u300d\u3068\u8ff0\u3079\u305f\u3002\u00a0<span class=\"xn-person\">\u30a2\u30ec\u30f3\u30fbC\u30fb\u30db\u30fc<\/span>, \u30a6\u30a3\u30eb\u30ba\u773c\u79d1\u75c5\u9662\u306e\u7db2\u819c\u7814\u7a76\u90e8\u9577\u517c\u7db2\u819c\u79d1\u5171\u540c\u90e8\u9577\u3067\u3042\u308a\u3001Nanoscope\u306e\u6700\u9ad8\u533b\u7642\u9867\u554f\u3067\u3082\u3042\u308b\u3001\u533b\u5b66\u535a\u58eb\u3001\u7c73\u56fd\u773c\u79d1\u5b66\u4f1a\u30d5\u30a7\u30ed\u30fc\u3001\u7c73\u56fd\u7db2\u819c\u5916\u79d1\u5b66\u4f1a\u30d5\u30a7\u30ed\u30fc\u3002\u300cFDA\u304b\u3089\u306e\u30d5\u30a3\u30fc\u30c9\u30d0\u30c3\u30af\u306fNanoscope\u306eBLA\u7533\u8acb\u8a08\u753b\u306b\u53cd\u6620\u3055\u308c\u3066\u304a\u308a\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3092\u69cb\u6210\u3059\u308b\u69d8\u3005\u306a\u9032\u884c\u6027\u7db2\u819c\u5909\u6027\u75c7\u306b\u3088\u3063\u3066\u8996\u529b\u3092\u5931\u3063\u305f\u60a3\u8005\u306b\u3068\u3063\u3066\u3001\u5b9f\u73fe\u53ef\u80fd\u306a\u8996\u529b\u56de\u5fa9\u306e\u9078\u629e\u80a2\u3068\u306a\u308b\u53ef\u80fd\u6027\u3092\u793a\u3057\u3066\u3044\u307e\u3059\u3002\u300d\u201c<\/p>\n<p>\u201c\u300c\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30c1\u30fc\u30e0\u306e\u5353\u8d8a\u3057\u305f\u5c02\u9580\u77e5\u8b58\u3068\u305f\u3086\u307e\u306c\u52aa\u529b\u306e\u304a\u304b\u3052\u3067\u3001FDA\u3068\u306e\u826f\u597d\u306a\u3084\u308a\u53d6\u308a\u304c\u3067\u304d\u305f\u3053\u3068\u3092\u5b09\u3057\u304f\u601d\u3044\u307e\u3059\u300d\u3068\u8ff0\u3079\u305f\u3002\u00a0<span class=\"xn-person\">\u30b9\u30e9\u30cb\u30e3\u30fb\u30d0\u30bf\u30c1\u30e3\u30ea\u30e4<\/span>, \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306e\u5171\u540c\u5275\u696d\u8005\u517c\u6700\u9ad8\u7d4c\u55b6\u8cac\u4efb\u8005\u3067\u3042\u308b\u5f7c\u306f\u6b21\u306e\u3088\u3046\u306b\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300c\u79c1\u305f\u3061\u306e\u5171\u901a\u306e\u76ee\u6a19\u306f\u4eba\u3005\u306e\u751f\u6d3b\u3092\u5909\u3048\u308b\u3053\u3068\u3067\u3042\u308a\u3001\u79c1\u305f\u3061\u306f\u5171\u306bMCO-010\u306e\u958b\u767a\u3092\u9032\u3081\u3001\u751f\u7269\u88fd\u5264\u627f\u8a8d\u7533\u8acb\uff08BLA\uff09\u306e\u6bb5\u968e\u306b\u307e\u3067\u81f3\u308a\u307e\u3057\u305f\u3002\u4e00\u6b69\u4e00\u6b69\u524d\u9032\u3059\u308b\u4e2d\u3067\u3001\u79c1\u305f\u3061\u306f\u6709\u610f\u7fa9\u306a\u8996\u529b\u56de\u5fa9\u3092\u5f85\u3061\u671b\u3080\u60a3\u8005\u3055\u3093\u306b\u7126\u70b9\u3092\u5f53\u3066\u3066\u3044\u307e\u3059\u3002\u79c1\u305f\u3061\u306e\u30c1\u30fc\u30e0\u306f\u3001\u30d1\u30fc\u30c8\u30ca\u30fc\u4f01\u696d\u3068\u5171\u306b\u3001\u3053\u306e\u6cbb\u7642\u6cd5\u3092\u5927\u304d\u306a\u30cb\u30fc\u30ba\u3092\u62b1\u3048\u308b\u60a3\u8005\u3055\u3093\u306b\u5c4a\u3051\u308b\u305f\u3081\u306b\u3001\u3053\u308c\u307e\u3067\u53d6\u308a\u7d44\u3093\u3067\u304d\u305f\u91cd\u8981\u306a\u6d3b\u52d5\u3092\u7d99\u7d9a\u3057\u3066\u3044\u304f\u3053\u3068\u3092\u697d\u3057\u307f\u306b\u3057\u3066\u3044\u307e\u3059\u3002\u300d\u201c<\/p>\n<p>\u201c\u300cFDA\u3068\u306e\u3053\u306e\u5b9f\u308a\u3042\u308b\u4f1a\u5408\u306f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u9ec4\u6591\u5909\u6027\u75c7\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u95a2\u3059\u308b\u6700\u8fd1\u306e\u7b2c2\u76f8\u7d42\u4e86\u4f1a\u8b70\u306b\u7d9a\u304f\u3082\u306e\u3067\u3042\u308a\u3001\u3053\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u306f\u7b2c3\u76f8\u767b\u9332\u8a66\u9a13\u3078\u3068\u9032\u3093\u3067\u3044\u307e\u3059\u300d\u3068\u8ff0\u3079\u305f\u3002\u00a0<span class=\"xn-person\">\u30b5\u30de\u30ec\u30f3\u30c9\u30e9\u30fb\u30e2\u30cf\u30f3\u30c6\u30a3<\/span>, \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306e\u793e\u9577\u517c\u6700\u9ad8\u79d1\u5b66\u8cac\u4efb\u8005\u3067\u3042\u308b\u535a\u58eb\u306f\u3001\u300cRESTORE\u8a66\u9a13\u3068REMAIN\u8a66\u9a13\u3092\u901a\u3058\u30663\u5e74\u9593\u3067\u8996\u529b\u6539\u5584\u304c\u8a8d\u3081\u3089\u308c\u305f\u3053\u3068\u306f\u3001\u3053\u306e\u9769\u65b0\u7684\u306a\u6cbb\u7642\u6cd5\u3092\u60a3\u8005\u306b\u5c4a\u3051\u308b\u3068\u3044\u3046\u5f53\u793e\u306e\u6c7a\u610f\u3092\u6539\u3081\u3066\u793a\u3059\u3082\u306e\u3067\u3059\u300d\u3068\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u201c<\/p>\n<p><b>\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306f\u3001\u7db2\u819c\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u308b\u7a00\u306a\u773c\u75be\u60a3\u306e\u30b0\u30eb\u30fc\u30d7\u3067\u3001\u5c0f\u5150\u671f\u306b\u75c7\u72b6\u304c\u73fe\u308c\u3001\u52b4\u50cd\u5e74\u9f62\u306e\u6210\u4eba\u306e\u5931\u660e\u306e\u4e3b\u306a\u539f\u56e0\u3068\u306a\u3063\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u306f\u907a\u4f1d\u6027\u75be\u60a3\u3067\u3042\u308a\u3001\u89aa\u304b\u3089\u6b20\u9665\u306e\u3042\u308b\u907a\u4f1d\u5b50\u3092\u4ecb\u3057\u3066\u5b50\u4f9b\u306b\u53d7\u3051\u7d99\u304c\u308c\u307e\u3059\u3002\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u3092\u5f15\u304d\u8d77\u3053\u3059\u53ef\u80fd\u6027\u306e\u3042\u308b\u907a\u4f1d\u5b50\u5909\u7570\u306f\u6570\u767e\u4ee5\u4e0a\u7279\u5b9a\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306e\u60a3\u8005\u3067\u306f\u3001\u5149\u3092\u611f\u77e5\u3059\u308b\u5149\u53d7\u5bb9\u4f53\u7d30\u80de\u304c\u52a3\u5316\u3057\u3001\u8996\u529b\u55aa\u5931\u306b\u3064\u306a\u304c\u308a\u307e\u3059\u3002\u73fe\u5728\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u3088\u308b\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u306b\u5bfe\u3059\u308b\u627f\u8a8d\u6e08\u307f\u306e\u6cbb\u7642\u6cd5\u306f\u3042\u308a\u307e\u305b\u3093\u3002\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306e\u60a3\u8005\u306e\u8996\u529b\u306e\u3055\u3089\u306a\u308b\u60aa\u5316\u3092\u9045\u3089\u305b\u305f\u308a\u3001\u9632\u3044\u3060\u308a\u3059\u308b\u3053\u3068\u304c\u6cbb\u7642\u76ee\u6a19\u3067\u3059\u3002<\/p>\n<p><b>MCO-010\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>MCO-010\uff08<i>\u30bd\u30f3\u30d4\u30ec\u30c1\u30b2\u30cd\u30fb\u30a4\u30b9\u30c6\u30d1\u30eb\u30dc\u30d9\u30af<\/i>MCO-010 \u30aa\u30d7\u30b7\u30f3\uff08\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u7528\u61f8\u6fc1\u6db2\uff09\u306f\u3001\u73fe\u5728\u81e8\u5e8a\u8a66\u9a13\u304c\u884c\u308f\u308c\u3066\u3044\u308b\u552f\u4e00\u306e\u5e83\u5e2f\u57df\u3001\u9ad8\u901f\u3001\u304b\u3064\u6700\u3082\u611f\u5ea6\u306e\u9ad8\u3044\u30aa\u30d7\u30b7\u30f3\u3067\u3059\u3002\u73fe\u5728\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u306f\u3001\u5916\u7db2\u819c\u7d30\u80de\u306b\u7279\u5b9a\u306e\u907a\u4f1d\u5b50\u5909\u7570\u3092\u6301\u3064\u60a3\u8005\u306e\u6cbb\u7642\u3092\u76ee\u7684\u3068\u3057\u3066\u3044\u307e\u3059\u304c\u3001\u8c4a\u5bcc\u306a\u5185\u7db2\u819c\u30cb\u30e5\u30fc\u30ed\u30f3\u3092\u6a19\u7684\u3068\u3059\u308b\u5468\u56f2\u5149\u6d3b\u6027\u5316 MCO \u30aa\u30d7\u30c8\u30b8\u30a7\u30cd\u30c6\u30a3\u30af\u30b9\u5358\u72ec\u7642\u6cd5\u306f\u3001\u5909\u6027\u3057\u305f\u5916\u7db2\u819c\u7d30\u80de\u3092\u6301\u3064\u9032\u884c\u6027 RP \u306b\u3088\u308b\u8996\u529b\u55aa\u5931\u3092\u56de\u5fa9\u3055\u305b\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002mGluR6 \u30d7\u30ed\u30e2\u30fc\u30bf\u30fc \u30a8\u30f3\u30cf\u30f3\u30b5\u30fc\u3092\u4ecb\u3057\u3066\u53cc\u6975\u7d30\u80de\u3092\u6a19\u7684\u3068\u3059\u308b MCO-010 \u767a\u73fe\u30ab\u30bb\u30c3\u30c8\u306f\u3001\u5b9f\u969b\u306e\u74b0\u5883\u3067\u9ad8\u54c1\u8cea\u306e\u8996\u529b\u3092\u56de\u5fa9\u3059\u308b\u3088\u3046\u306b\u8a2d\u8a08\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u72ec\u81ea\u306e AAV2 \u30d9\u30af\u30bf\u30fc\u306b\u3088\u308a\u3001\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u306b\u3088\u308a\u53cc\u6975\u7d30\u80de\u3078\u306e MCO-010 \u306e\u5805\u7262\u306a\u5c0e\u5165\u304c\u53ef\u80fd\u306b\u306a\u308a\u307e\u3059\u3002\u9032\u884c\u6027 RP \u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f MCO-010 \u306e\u7b2c 1\/2 \u76f8\u8a66\u9a13\u3067\u306f\u3001\u8996\u899a\u8a98\u5c0e\u6027\u79fb\u52d5\u3001\u5f62\u72b6\u8b58\u5225\u3001\u304a\u3088\u3073\u8996\u529b\u306e\u6539\u5584\u304c\u5b9f\u8a3c\u3055\u308c\u307e\u3057\u305f\u3002\u30e9\u30f3\u30c0\u30e0\u5316\u4e8c\u91cd\u76f2\u691c\u591a\u65bd\u8a2d\u5171\u540c RESTORE \u8a66\u9a13\u3067 MCO-010 \u306b\u3088\u308b\u6cbb\u7642\u3092\u53d7\u3051\u305f\u60a3\u8005\u306e\u304b\u306a\u308a\u306e\u5272\u5408\u3067\u3001\u8996\u899a\u8a98\u5c0e\u79fb\u52d5\u304a\u3088\u3073\u5f62\u72b6\u8b58\u5225\u306b\u3088\u3063\u3066\u8a55\u4fa1\u3055\u308c\u305f\u6700\u9ad8\u77ef\u6b63\u8996\u529b\u304a\u3088\u3073\u6a5f\u80fd\u7684\u8996\u529b\u306e\u6539\u5584\u304c\u898b\u3089\u308c\u3001\u307e\u305f\u3001\u826f\u597d\u306a\u5b89\u5168\u6027\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3082\u793a\u3055\u308c\u307e\u3057\u305f\u3002<\/p>\n<p><b>\u305d\u306e\u4ed6\u306e\u81e8\u5e8a\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8<br class=\"dnr\" \/><\/b>\u540c\u793e\u306f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fMCO-010\u7642\u6cd5\u306e\u7b2c2\u76f8STARLIGHT\u8a66\u9a13\u3092\u5b8c\u4e86\u3057\u305f\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\uff09\u305d\u3057\u3066\u6700\u8fd1\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">\u7b2c3\u30d5\u30a7\u30fc\u30ba\u3092\u958b\u59cb\u3059\u308b\u8a08\u753b\u3092\u767a\u8868\u3057\u305f<\/a>\u00a02025\u5e74\u7b2c1\u56db\u534a\u671f\u306b\u767b\u9332\u8a66\u9a13\u3092\u5b9f\u65bd\u3057\u307e\u3059\u3002<\/p>\n<p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306f\u3001\u6cbb\u7642\u6cd5\u304c\u5b58\u5728\u3057\u306a\u3044\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u3063\u3066\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u8996\u529b\u56de\u5fa9\u5149\u907a\u4f1d\u5b66\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u540c\u793e\u306e\u4e3b\u8981\u8cc7\u7523\u3067\u3042\u308bMCO-010\u306f\u3001\u6700\u8fd1\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>\uff09\u3002MCO-010 \u306f\u3001RP \u3068 Stargardt \u306e\u4e21\u65b9\u3067 FDA \u30d5\u30a1\u30b9\u30c8 \u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3068 FDA \u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u524d\u81e8\u5e8a\u8cc7\u7523\u306b\u306f\u3001\u5730\u56f3\u72b6\u840e\u7e2e\u306b\u5bfe\u3059\u308b\u975e\u30a6\u30a4\u30eb\u30b9\u6027\u30ec\u30fc\u30b6\u30fc\u9001\u9054 MCO-020 \u907a\u4f1d\u5b50\u6cbb\u7642\u304c\u542b\u307e\u308c\u307e\u3059\u3002<\/p>\n<p><b>\u6295\u8cc7\u5bb6\u9023\u7d61\u5148:<\/b><br class=\"dnr\" \/>\u30a2\u30eb\u30b4\u30c3\u30c8\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba<br class=\"dnr\" \/>(212) 600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>Productive FDA meeting\u00a0paves the way for BLA submission for MCO-010 in Q1 2025 DALLAS, TX \u2014 Oct. 10, 2024\u00a0 \u2014 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases today announced a productive FDA meeting for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP). Based on the regulatory feedback provided in the meeting, Nanoscope will commence with submission of a Biologics License Application (BLA) in Q1 2025. In connection with the meeting, the FDA acknowledged Nanoscope\u2019s proposed next steps to facilitate a BLA submission for MCO-010 for the treatment of severe vision loss due to RP. Nanoscope outlined its plans [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5827,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5822","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-10T11:39:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T13:35:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/10\\\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/10\\\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa\",\"datePublished\":\"2024-10-10T11:39:10+00:00\",\"dateModified\":\"2025-06-27T13:35:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/10\\\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\\\/\"},\"wordCount\":823,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/10\\\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_LI_RP_BLA_V6.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/10\\\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/10\\\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\\\/\",\"name\":\"Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/10\\\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/10\\\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_LI_RP_BLA_V6.jpg\",\"datePublished\":\"2024-10-10T11:39:10+00:00\",\"dateModified\":\"2025-06-27T13:35:21+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/10\\\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/10\\\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/10\\\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_LI_RP_BLA_V6.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_LI_RP_BLA_V6.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/10\\\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u85acMCO-010\u306e\u751f\u7269\u88fd\u5264\u627f\u8a8d\u7533\u8acb\uff08BLA\uff09\u3092\u884c\u3046\u8a08\u753b\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-10-10T11:39:10+00:00","article_modified_time":"2025-06-27T13:35:21+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"4\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa","datePublished":"2024-10-10T11:39:10+00:00","dateModified":"2025-06-27T13:35:21+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/"},"wordCount":823,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_RP_BLA_V6.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/","url":"https:\/\/nanostherapeutics.com\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u6cbb\u7642\u85acMCO-010\u306e\u751f\u7269\u88fd\u5264\u627f\u8a8d\u7533\u8acb\uff08BLA\uff09\u3092\u884c\u3046\u8a08\u753b\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_RP_BLA_V6.jpg","datePublished":"2024-10-10T11:39:10+00:00","dateModified":"2025-06-27T13:35:21+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_RP_BLA_V6.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_RP_BLA_V6.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5822","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=5822"}],"version-history":[{"count":3,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5822\/revisions"}],"predecessor-version":[{"id":9015,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5822\/revisions\/9015"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/5827"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=5822"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=5822"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=5822"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}